Crinetics Pharmaceuticals
CRNX
266 hedge funds and large institutions have $4.63B invested in Crinetics Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 98 increasing their positions, 71 reducing their positions, and 31 closing their positions.
84% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 31
38% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 71
36% more call options, than puts
Call options by funds: $2.32M | Put options by funds: $1.7M
9% more funds holding
Funds holding: 243 → 266 (+23)
4% more capital invested
Capital invested by funds: $4.46B → $4.63B (+$169M)
0.02% more ownership
Funds ownership: 117.26% → 117.28% (+0.02%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$84.5M |
| 2 |
BlackRock
New York
|
+$47.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.9M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$24.2M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$22.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$156M |
| 2 |
RI
RTW Investments
New York
|
-$52.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$38.1M |
| 4 |
Jennison Associates
New York
|
-$27.6M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$24.5M |
CRNX Hedge Fund Activity: Q2 2026 in Review
266 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2026, worth a combined $4.63B — up 3.8% from $4.46B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new CRNX positions and 31 closed out — a net gain of 26 holders — while 98 added to existing stakes and 71 trimmed.
The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $84.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $156M sold.
- 266 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2026, up from 243 in Q1 2026.
- Funds reported $4.63B of Crinetics Pharmaceuticals stock for Q2 2026, up 3.8% quarter-over-quarter.
- 57 funds opened new Crinetics Pharmaceuticals positions in Q2 2026 and 31 closed out, a net change of +26 holders.
- The largest Crinetics Pharmaceuticals buyer in Q2 2026 was Polar Capital Holdings, an estimated $84.5M added.
- The largest Crinetics Pharmaceuticals seller in Q2 2026 was EcoR1 Capital, an estimated $156M sold.
Based on aggregated 13F filings for Q2 2026.